home / stock / janx / janx news


JANX News and Press, Janux Therapeutics Inc. From 03/10/24

Stock Information

Company Name: Janux Therapeutics Inc.
Stock Symbol: JANX
Market: NASDAQ
Website: januxrx.com

Menu

JANX JANX Quote JANX Short JANX News JANX Articles JANX Message Board
Get JANX Alerts

News, Short Squeeze, Breakout and More Instantly...

JANX - Big Pharma patent cliffs seen fueling oncology M&A this year

2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

JANX - Janux Therapeutics GAAP EPS of -$0.25 beats by $0.16, revenue of $2.46M beats by $1.72M

2024-03-08 16:06:21 ET More on Janux Therapeutics Janux Therapeutics: Yes There's New Data; No It's Not A Buy Here Trial Data Triggers Massive Rally In Janux Therapeutics Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024 Janux T...

JANX - Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC and for EGFR-TRACTr JANX008 in solid tumors Enrollment ongoing for JANX007 and JANX008 Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024 $344.0 ...

JANX - Expected US Company Earnings on Friday, March 8th, 2024

Genesco Inc. (GCO) is expected to report $2.66 for Q4 2024 Broadway Financial Corporation (BYFC) is expected to report for quarter end 2023-12-31 Oji Holdings Corporation ADR (OJIPY) is expected to report for Q3 2024 Hibbett Inc. (HIBB) is expected to report $2.54 for Q4 2024 GRI ...

JANX - Top 10 best performing biotech stocks of 2024 so far

2024-03-06 11:25:10 ET Over the past 3 months the biotech space is +30.4% and has only been outperformed by semiconductors, computer processing hardware and the computer peripherals industries. Additionally, the biotech sector is +13.6% in 2024, outdoing all of the major market aver...

JANX - (JANX) Investment Analysis

2024-03-03 01:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

JANX - After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?

2024-03-02 06:56:00 ET With shares of Janux Therapeutics (NASDAQ: JANX) exploding upward to a high of more than 222% above its prior closing price on Feb. 27, it is no great shock that many investors are wondering whether the stock is still worth buying. The market is interpreting t...

JANX - Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today anno...

JANX - US Companies Moving the Markets, Morning edition
Wed, Feb 28, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...

JANX - Janux Therapeutics Announces Proposed Public Offering of Common Stock

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today anno...

Previous 10 Next 10